Qiuqing Wang

4 weeks ago | jamanetwork.com | Steven Nissen |Qiuqing Wang |Stephen Nicholls |Ann Marie Navar

Zerlasiran for the Treatment of Atherosclerotic Cardiovascular Disease—Reply Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a) Steven E. Nissen, MD; Qiuqing Wang, MS; Stephen J. Nicholls, MBBS, PhD; Ann Marie Navar, MD, PhD; Kausik K. Ray, MD, MPhil; Gregory G. Schwartz, MD, PhD; Michael Szarek, PhD; Erik S. G. Stroes, MD, PhD; Roland Troquay, MD; Jannick A. N. Dorresteijn, MD, PhD; Henry Fok, MBBS, PhD; David A.

Nov 18, 2024 | jamanetwork.com | Steven Nissen |Qiuqing Wang |Stephen Nicholls |Ann Marie Navar

Key PointsQuestion  What is the effect of zerlasiran on time-averaged lipoprotein(a) serum concentrations during 36 weeks of treatment? Findings  In 178 patients with cardiovascular disease and lipoprotein(a) concentrations greater than or equal to 125 nmol/L, the least-squares mean placebo-adjusted time-averaged percent change in lipoprotein(a) serum concentrations was −85.6%, −82.8%, and −81.3% for the 450 mg every 24 weeks, 300 mg every 16 weeks, and 300 mg every 24 weeks groups, respectively.